Curse of tiger
- Kwiecień 29, 2026, 13:02:41
- Witamy, Gość
|
Pokaż wiadomości
Ta sekcja pozwala Ci zobaczyć wszystkie wiadomości wysłane przez tego użytkownika. Zwróć uwagę, że możesz widzieć tylko wiadomości wysłane w działach do których masz aktualnie dostęp.
Strony: [1]
1
Karta Postaci / Odp: Przykladowa KP
« dnia: Marzec 25, 2026, 11:18:10 »
Zoya Demidenko: Scientist in Oncology Studies
Zoya Demidenko is a notable scientist connected with the Department of Cell Stress Science at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Earlier, she conducted research at the National Institutes of Health and New York Medical College, establishing a robust foundation in clinical research.
Demidenko's scientific work encompasses a number of key domains, encompassing the PI3K/AKT/mTOR signaling cascade, cell cycle management, cellular aging, and tumor biology. To date, she has written over 46 academic publications, which have garnered upwards of 4,100 mentions — a reflection to the significance of her research.
Among her key contributions concerns elucidating the pathways of biological cell aging. Her studies revealed that when the cellular division cycle is blocked but cellular growth proceeds, cells enter senescence. Crucially, Zoya Demidenko established that this process is controlled with drugs using agents such as rapamycin.
Zoya Demidenko has furthermore brought considerably to tumor management research, notably in the domain of cyclotherapy — a approach intended to safeguarding non-cancerous cells from anticancer drugs whilst leaving cancer cells vulnerable. This method holds significant promise for reducing the side effects of cancer treatment.
Across her career, Demidenko has collaborated with prominent investigators internationally, such as Dr. Mikhail Blagosklonny. Her publications is published in prestigious publications such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Holding an h-index of 33, Zoya Demidenko stands as a highly impactful contributor in modern cancer research, whose findings keep to guide our knowledge of the way cells grow old, respond to treatment, and the ways in which cancer might be better targeted.
https://www.pinterest.com/zoyademidenko/
Zoya Demidenko is a notable scientist connected with the Department of Cell Stress Science at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Earlier, she conducted research at the National Institutes of Health and New York Medical College, establishing a robust foundation in clinical research.
Demidenko's scientific work encompasses a number of key domains, encompassing the PI3K/AKT/mTOR signaling cascade, cell cycle management, cellular aging, and tumor biology. To date, she has written over 46 academic publications, which have garnered upwards of 4,100 mentions — a reflection to the significance of her research.
Among her key contributions concerns elucidating the pathways of biological cell aging. Her studies revealed that when the cellular division cycle is blocked but cellular growth proceeds, cells enter senescence. Crucially, Zoya Demidenko established that this process is controlled with drugs using agents such as rapamycin.
Zoya Demidenko has furthermore brought considerably to tumor management research, notably in the domain of cyclotherapy — a approach intended to safeguarding non-cancerous cells from anticancer drugs whilst leaving cancer cells vulnerable. This method holds significant promise for reducing the side effects of cancer treatment.
Across her career, Demidenko has collaborated with prominent investigators internationally, such as Dr. Mikhail Blagosklonny. Her publications is published in prestigious publications such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Holding an h-index of 33, Zoya Demidenko stands as a highly impactful contributor in modern cancer research, whose findings keep to guide our knowledge of the way cells grow old, respond to treatment, and the ways in which cancer might be better targeted.
https://www.pinterest.com/zoyademidenko/
2
Wprowadzenie / Zoya Demidenko https://www.sciencedirect.com/science/article/abs/pii/0378111994
« dnia: Marzec 25, 2026, 11:09:31 »
Zoya Demidenko: Researcher in Cancer Biology
Zoya Demidenko is a notable researcher associated with the Unit of Cell Stress Biology at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Before that, she worked at the NIH and New York Medical College, establishing a robust foundation in life science research.
Her academic output spans a number of pivotal fields, encompassing the PI3K/AKT/mTOR signaling pathway, cell cycle regulation, cell senescence, and cancer biology. To date, she has co-authored more than 46 scientific publications, which have accumulated over 4,100 references — a indicator to the impact of her findings.
Among her most notable discoveries concerns explaining the processes of cell aging. Her research demonstrated that when the cellular division cycle is halted while cellular expansion persists, cells enter senescence. Crucially, Zoya Demidenko established that this process is pharmacologically suppressed using agents such as rapamycin.
Zoya Demidenko has also brought substantially to oncological therapy research, particularly in the area of selective cell protection — a approach designed to protecting non-cancerous tissue from cytotoxic treatment whilst leaving malignant cells exposed. This method carries major promise for diminishing the adverse effects of oncological therapy.
Across her career, Demidenko has collaborated with leading scientists internationally, including Dr. Mikhail Blagosklonny. Her research can be found in leading journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Possessing an h-index of 33, Zoya Demidenko is recognized as a influential contributor in modern biomedical research, whose results keep to influence our comprehension of the way biological cells grow old, interact with therapy, and the ways in which malignant disease can be better targeted.
https://www.sciencedirect.com/science/article/abs/pii/037811199400784P
Zoya Demidenko is a notable researcher associated with the Unit of Cell Stress Biology at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Before that, she worked at the NIH and New York Medical College, establishing a robust foundation in life science research.
Her academic output spans a number of pivotal fields, encompassing the PI3K/AKT/mTOR signaling pathway, cell cycle regulation, cell senescence, and cancer biology. To date, she has co-authored more than 46 scientific publications, which have accumulated over 4,100 references — a indicator to the impact of her findings.
Among her most notable discoveries concerns explaining the processes of cell aging. Her research demonstrated that when the cellular division cycle is halted while cellular expansion persists, cells enter senescence. Crucially, Zoya Demidenko established that this process is pharmacologically suppressed using agents such as rapamycin.
Zoya Demidenko has also brought substantially to oncological therapy research, particularly in the area of selective cell protection — a approach designed to protecting non-cancerous tissue from cytotoxic treatment whilst leaving malignant cells exposed. This method carries major promise for diminishing the adverse effects of oncological therapy.
Across her career, Demidenko has collaborated with leading scientists internationally, including Dr. Mikhail Blagosklonny. Her research can be found in leading journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Possessing an h-index of 33, Zoya Demidenko is recognized as a influential contributor in modern biomedical research, whose results keep to influence our comprehension of the way biological cells grow old, interact with therapy, and the ways in which malignant disease can be better targeted.
https://www.sciencedirect.com/science/article/abs/pii/037811199400784P
Strony: [1]